These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722 [TBL] [Abstract][Full Text] [Related]
24. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575 [TBL] [Abstract][Full Text] [Related]
25. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance. Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462 [TBL] [Abstract][Full Text] [Related]
27. Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. Kayatani H; Ohashi K; Ninomiya K; Makimoto G; Nishii K; Higo H; Watanabe H; Kano H; Kato Y; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K Biochem Biophys Res Commun; 2020 Nov; 532(3):341-346. PubMed ID: 32888648 [TBL] [Abstract][Full Text] [Related]
28. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765 [TBL] [Abstract][Full Text] [Related]
29. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
31. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385 [TBL] [Abstract][Full Text] [Related]
33. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276 [TBL] [Abstract][Full Text] [Related]
34. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329 [TBL] [Abstract][Full Text] [Related]
35. Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Bagnyukova T; Egleston BL; Pavlov VA; Serebriiskii IG; Golemis EA; Borghaei H Cancer Res Commun; 2024 May; 4(5):1227-1239. PubMed ID: 38639476 [TBL] [Abstract][Full Text] [Related]
37. Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Ko JL; Lin CH; Chen HC; Hung WH; Chien PJ; Chang HY; Wang BY Environ Toxicol; 2018 Nov; 33(11):1153-1159. PubMed ID: 30136359 [TBL] [Abstract][Full Text] [Related]
39. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012 [TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]